GENE ONLINE|News &
Opinion
Blog

2018-10-05| Startups

Cambridge startup, GO Therapeutics make $195 million deal with Roche

by Rajaneesh K. Gopinath
Share To

This agreement grants Roche exclusive license for antibodies generated against novel cancer-specific targets and to develop a new glycotargeting bispecific antibody.

By Rajaneesh K Gopinath

GO Therapeutics Inc. (GO), an immuno-oncology startup company headquartered at Cambridge was founded in 2014. It applies new advances in glycoproteomics to develop potent, yet toxic free cancer therapeutics that are antibody-based. On October 2nd, the company announced that it has entered into a license agreement with Roche. This collaboration would facilitate the entry of its drug into the clinic by 2020. According to this agreement, Roche will pay GO $9 million upfront and the remaining $186 million in milestone payments. On top of this, GO would also receive royalties on any future product sales.

Constantine Theodoropulos, the chief executive officer of GO Therapeutics expressed his excitement over the deal. “We are excited about this collaboration to develop an innovative immune-redirected therapy to potentially improve the lives of patients suffering from cancer in the future,” he said in a statement. “GO’s glycoprotein targeting platform opens an exciting class of tumor-specific antigens that can help widen the therapeutic window for cancer therapies such as T-cell bispecific antibodies, CAR-T and ADCs (Antibody Drug Conjugates). Preclinical data show GO’s approach can provide superior specificity in targeting solid tumors over normal tissue, and demonstrate clean in-vivo toxicity profiles in the context of potent immunotherapies.”

Roche is expected to begin clinical trials on the licensed drug candidate in 2020, with GO starting clinical trials on its own drug candidate next year. GO is also developing a pipeline of other antibodies targeted against lymphomas, glioblastomas, liver, kidney and lung cancer tumors.

References

  1. http://gotherapeutics.com/2018/10/go-therapeutics-enters-into-a-license-agreement-with-roche-for-new-glycotargeting-bispecific-cancer-treatment/
  2. https://www.bizjournals.com/boston/news/2018/10/02/cancer-startup-go-therapeutics-eyes-clinic-after.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Roche’s Polivy Wins Support From FDA Adcom For Treating B-Cell Cancer
2023-03-10
Roche Returns Gavreto Rights To Blueprint After Ditching Collaboration
2023-02-24
R&D
Latest Discovery in Metabolic Pathways of T-Cells Opens New Door to Immunology Research
2023-02-23
LATEST
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Ways to Reduce Carbon Emission in Cement Manufacturing
2023-03-26
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
Scroll to Top